Systemic Anti-Cancer Therapies in Neuroendocrine Tumor Patients Impair Nutritional Status Abstract #2098

Introduction: Malnutrition is a clinical relevant problem in NEN-patients (pts) independently influencing overall prognosis, particularly in pts undergoing chemotherapy (CTx). A poor nutritional status (NS) in pts of all WHO-grades was associated with a significantly shorter long-term outcome
Aim(s): This prospective observational longitudinal study investigates the influence of a systemic medical treatment initiation due to progressive disease on NS in NET G1/G2 pts
Materials and methods: Subjective Global Assessment (SGA), body weight (BW), bioelectrical impedance analysis (BIA) and anthropometry parameters were regularly assessed before and during therapy
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Sophie Pevny

To read results and conclusion, please login ...

Further abstracts you may be interested in

#136 Prevalence, severity and clinical outcome of malnutrition in gastroenteropancreatic neuroendocrine tumors
Introduction: Malnutrition is well-known to unfavorably influence clinical prognosis in patients (pts) with malignant diseases. However, in patients with neuroendocrine tumors (NET) prevalence and outcome of malnutrition are unknown although the gastroenteropancreatic system is most frequently involved.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr Sebastian Maasberg
#241 One-year Response to Everolimus in a Case of Advanced Pancreatic NET
Introduction: A stage IV pancreatic NET (30 mitoses/10 PF and Ki-67 index=40%) with liver and peritoneal metastases was diagnosed in a 35-year-old woman in June 2008. Characteristics: ECOG2 and CgA 1701 ng/ml.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#258 Diagnosis and Management of Thymic Neuroendocrine Tumors: A Case Series Review
Introduction: Thymic neuroendocrine tumors (TNET) represent rare types of thymic tumors with an incidence of 0.01/100000 per year. They commonly show rapid disease progression and are rarely curable.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Christos Toumpanakis
#732 Impact of Prior Chemotherapy (CT) and Somatostatin Analogues (SSAs) on Clinical Outcome in Well-Differentiated Pancreatic Neuroendocrine Tumors (pWDNETs) before Treatment of Everolimus (EV)
Introduction: In the phase III RADIANT-3 trial, EV demonstrated a significant improvement in PFS with a median of 11.0 v. 4.6 months (mo) for placebo in pWDNETs pts.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: dr Sara Pusceddu
Keywords: everolimus
#1200 Clinical Outcome of Everolimus Treatment of Advanced Neuroendocrine Neoplasms: “Real-life” Data from the German NET-Register
Introduction: Everolimus (EVE) has importantly impacted the treatment (Tx) of mostly pancreatic NEN.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Sebastian Maasberg
Authors: Pape U F, Bacher M, Fottner C, Lahner H, ...
Keywords: everolimus, outcome